Mon, 30 November 2020
In a follow-up to our recent episode featuring Optios’ CEO David Bach, M.D., today Hall welcomes both David and Paul Sajda, Ph.D. professor at Columbia University to discuss the science behind Optios. Optios is a leader in the rapidly-emerging neuro-performance industry. Based on more than a decade of work at DARPA, hundreds-of-millions of dollars of proprietary research, and close partnerships with the world’s most elite organizations, Optios’ guiding mission is to build an intellectual framework and platform that supports the next phase in human development. Neuroscience is the next frontier in management. Optimizing leaders’ brains will soon be a critical source of competitive advantage in the business world. David Bach, M.D. is a Harvard-trained scientist. Prior to founding Optios, David was a serial entrepreneur, venture capitalist, management consultant, scientist, physician, martial artist, and professional cellist. As an entrepreneur, he founded and built three prior companies: Touchstone Health, Empyrean Benefit Solutions, and Leprechaun HCC Management. Each of these became a $200M+ enterprise. His venture capital experience was with TA Associates in Boston. After spending a decade maximizing his physical and mental performance, David created Optios to bring scientific rigor to, and create commercial applications in, the rapidly-expanding arena of applied neuroscience. David attended Harvard College and Harvard Medical School. His scientific training was at The Dana-Farber Cancer Institute. Paul Sajda, Ph.D. is a Professor of Biomedical Engineering, Electrical Engineering and Radiology at Columbia University and Director of the Laboratory for Intelligent Imaging and Neural Computing. Prior to joining the faculty at Columbia, Paul was the head of Image and Signal Processing at Sarnoff Corporation in Princeton, NJ. His areas of expertise include computational and experimental neuroscience, neuroimaging, neural engineering, and computational modeling. He has received numerous awards for his research, including an NSF CAREER Award, and has been elected a Fellow of the IEEE, a Fellow of the American Institute of Medical and Biological Engineers (AIMBE), and a Fellow of the American Association for the Advancement of Science (AAAS). You can visit Optios at www.optios.com. David can be contacted via email at david@optios.com and Paul can be contacted via email at pauls@optios.com.
Direct download: Behind_the_Science_-_Optios_sector_review.mp3
Category:general -- posted at: 11:57am CST |
Mon, 30 November 2020
Hello, this is Hall T. Martin with the Startup Funding Espresso -- your daily shot of startup funding and investing. Raising a fund is hard. Aside from sales, this is one of the hardest things to do in a startup. Here are a few points to remember in your fundraise:
It’s a process -- for every 10 prospects you’ll get 8 “Nos”, 1 maybe, and eventually 1 “Yes”. Keep going ‘til the money is in the bank. For more episodes from Investor Connect, please visit the site at: http://investorconnect.org Check out our other podcasts here: https://investorconnect.org/ For Feedback please contact info@tencapital.group
Direct download: Startup_Funding_Espresso_--_Raising_funding_is_hard.mp3
Category:general -- posted at: 7:00am CST |